Integral Ad Science Holding Corp. shares rise 3.20% intraday after Roche's ALIENTO study met primary endpoint.

Integral Ad Science Holding Corp. rose 3.20% in intraday trading, with Roche announcing the results of its pivotal phase IIb ALIENTO study, which met the primary endpoint of a statistically significant reduction in the annualised exacerbation rate (AER) at 52 weeks when astegolimab was given every two weeks. However, the phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks. The safety profile of astegolimab was consistent with previously reported data, with no new safety signals identified.